Mandatory Minimum Sentence: Not Scheduled, Does Not Apply; Legal by Prescription
Mechanism of Action: Increases the Neurotransmitter Serotonin
Fluvoxamine (brand name as Luvox®, Faverin®, Fevarin® and Dumyrox®) was one of the first of the SSRI antidepressants to be launched (1984 - Switzerland) and was developed by Solvay Pharmaceuticals. It has been in use in clinical practice since 1983 and has a clinical trial database comprising of approximately 35,000 patients.
It was launched in the US in December 1994 and in Japan in June 1999. More than 10 million patients world-wide have been treated with fluvoxamine. Fluvoxamine was the first SSRI to be registered for the treatment of Obsessive Compulsive Disorder in children by FDA in 1997. Fluvoxamine was the first drug approved for the treatment of social anxiety disorder in Japan in 2005.
Side Effects and Adverse Reactions:
Common side effects of fluvoxamine are: nausea, vomiting, drowsiness, difficulty sleeping, dizziness, nervousness, feeling anxious, dry mouth, abdominal pain, constipation, diarrhea, heart burn, loss of appetite, muscle weakness, pins and needles, abnormal taste, headache, faster heart beat, sweating, weight gain, weight loss or unusual bruising. Other side effects observed more frequently in children are: abnormal thoughts or behaviour, cough, increased period pain, nose bleeds, increased restlessness, infection and sinusitis.
Sexual side effects with fluvoxamine are rare, unlike other SSRIs.